No effect of IL-17 gene expression on overall survival probability was found; however, association with progression free survival probability was identified as a 0.35 progression-free survival probability 24 months after tumor resection in patients with low expression of IL-17 in tumors vs. 0.2 in tumors with high expression. This evidence concerns the gene IL17A and neoplasm.